First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study

Vertex Receives FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes

Aluna Raises USD 15.3m in Series B Funding

First Patient Dosed in Adaptive Phage Therapeutics' PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection

CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy

Markels Named to Arcturus Therapeutics Board of Directors

SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis

Sionna Therapeutics receives approval from US Food and Drug Administration for Investigational New Drug application of SION-638

Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera

Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206

US FDA Approves Orkambi in Children with Cystic Fibrosis Ages 12 to <24 Months

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine